Target intelligence / Profile preview

Tyrosine-protein kinase Fer (FER)

Target
FER
Molecular classification
Enzyme, Cytoplasmic tyrosine kinase, Non-receptor tyrosine kinase, Proto-oncogene protein
01

Overview

Tyrosine-protein kinase Fer (FER) is a cytoplasmic non-receptor tyrosine kinase of the FPS/FES family, involved in the regulation of signal transduction downstream of several cell surface growth factor receptors including EGFR, PDGFR, and KIT[2][3][5][6]. FER is implicated in the control of actin cytoskeleton organization, cell adhesion, migration, proliferation, and chemotaxis, and has roles in immune responses, mast cell degranulation, leukocyte recruitment, and neuronal signaling[2][3][6][7]. Dysregulation of FER function has been linked to cancer pathogenesis and inflammatory and neurodegenerative processes. It interacts with key molecules such as catenins and focal adhesion kinase, and can phosphorylate substrates including CTTN, CTNND1, PTK2/FAK1, GAB1, PECAM1, PTPN11, and potentially STAT3[2][3][5]. FER participates in various signaling pathways that are fundamental in both physiological and pathological cellular processes.

Other names
TYK3PPP1R74proto-oncogene c-Ferp94-FerFeline encephalitis virus-related kinase FERFujinami poultry sarcoma/Feline sarcoma-related protein Ferphosphoprotein NCP94protein phosphatase 1, regulatory subunit 74
02

Mechanism of action

Inhibition of tyrosine kinase activity (by kinase inhibitors such as fostamatinib)[3]

03

Biological functions

Signal transductionRegulation of actin cytoskeletonCell adhesionCell migrationChemotaxisRegulation of mitotic cell cycleInsulin receptor signalingActivation of phosphatidylinositol 3-kinaseRegulation of mast cell degranulationSynapse organization and neurotransmission
04

Disease associations

CancerInflammationNeuronal cell deathSkin amelanotic melanomaCeroid lipofuscinosis (neuronal, 6A)
05

Safety considerations

Potential unintended inhibition of FER by multi-kinase inhibitors may impact immune regulation, cytoskeletal dynamics, and neuronal function[3]
06

Interacting drugs

Fostamatinib (inhibitor, off-target activity)

1 more in the full profile.

07

Biomarkers

null (no established clinical biomarkers for patient selection or efficacy monitoring specific to FER identified in reviewed sources)

Beyond the preview

Go deeper on Tyrosine-protein kinase Fer (FER).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tyrosine-protein kinase Fer (FER).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call